アジア太平洋炭疽菌治療市場 - 2029年までの業界動向と予測

Request for TOC TOC のリクエスト Speak to Analyst アナリストに相談する Buy Now今すぐ購入 Inquire Before Buying 事前に問い合わせる Free Sample Report 無料サンプルレポート

アジア太平洋炭疽菌治療市場 - 2029年までの業界動向と予測

  • Pharmaceutical
  • Published Report
  • Aug 2022
  • Asia-Pacific
  • 350 ページ
  • テーブル数: 454
  • 図の数: 38

アジア太平洋炭疽菌治療市場、タイプ別(皮膚炭疽菌、肺炭疽菌、腸炭疽菌)、投与経路別(経口、非経口、その他)、エンドユーザー別(政府機関、病院、学術研究機関、その他) - 2029年までの業界動向と予測。

アジア太平洋炭疽菌治療市場

アジア太平洋炭疽菌治療市場の分析と洞察

アジア太平洋地域の炭疽菌治療市場は、細菌感染の発生率の上昇、研究資金の増加、炭疽菌治療の新しい治療法の開発、パイプライン製品による需要の増大、研究開発への投資の増加などの要因によって牽引されており、市場の成長につながっています。現在、先進国と新興国全体で医療費が増加しており、メーカーが新しい革新的な製品を開発するための競争上の優位性が生まれると予想されています。

アジア太平洋炭疽菌治療市場

アジア太平洋炭疽菌治療市場

炭疽菌に苦しむ人々の数が世界中で増加していることは、炭疽菌治療市場の成長を牽引する主な要因の 1 つです。新しい治療法を開発する研究者への資金援助の増加、および民間人や軍隊における炭疽菌への曝露の脅威の増加が、市場の成長を加速させています。研究開発プログラムの数の増加、および革新的で効果的な治療法の新たな開発を促進するための官民パートナーシップの増加は、市場にさらなる影響を与えています。ただし、治療と手順に関連する高コスト、および製品承認に関する厳格な政府規制が、炭疽菌治療市場の成長を妨げると予想されます。

アジア太平洋炭疽菌治療市場レポートは、市場シェア、新開発、製品パイプライン分析、国内および現地の市場プレーヤーの影響の詳細を提供し、新たな収益源、市場規制の変更、製品承認、戦略的決定、製品発売、地理的拡大、市場における技術革新の観点からの機会を分析します。分析と市場シナリオを理解するには、アナリスト概要についてお問い合わせください。当社のチームが、収益に影響を与えるソリューションを作成し、目的の目標を達成するお手伝いをします。さまざまな地域の発展途上国における小売ユニットの拡張性と事業拡大、および機械および医薬品製品の安全な流通のためのサプライヤーとのパートナーシップは、予測期間における市場の需要を推進した主な原動力です。

アジア太平洋地域の炭疽菌治療市場は、病気の進行を抑えることを目標としており、支援的である。データブリッジ・マーケット・リサーチは、アジア太平洋地域の炭疽菌治療市場は、2022年から2029年の予測期間中に7.0%のCAGRで成長すると分析している。

レポートメトリック

詳細

予測期間

2022年から2029年

基準年

2021

歴史的な年

2020 (2019 - 2014 にカスタマイズ可能)

定量単位

売上高は百万米ドル、価格は米ドル

対象セグメント

タイプ別(皮膚炭疽、肺炭疽、腸炭疽)、投与経路別(経口、非経口、その他)、エンドユーザー別(政府機関、病院、学術研究機関、その他)業界動向と2029年までの予測

対象国

日本、中国、インド、韓国、オーストラリア、シンガポール、マレーシア、タイ、インドネシア、フィリピン、その他のアジア太平洋諸国

対象となる市場プレーヤー

Alembic Pharmaceuticals、Sun Pharmaceutical Industries Ltd.、Zydus Group、Bayer AG、Pfizer Inc.、EMERGENT、Sanofi、Lupin、武田薬品工業株式会社、Teva Pharmaceutical Industries Ltd.、ARISTO Pharmaceuticals Private Limited、INDOCO REMEDIES LTD.、GC Biopharma, corp.など

アジア太平洋炭疽菌治療市場の動向 

市場の定義

炭疽病は、炭疽菌 (B. anthracis) と呼ばれる細菌によって引き起こされます。これは主に、土壌中の胞子を摂取することで感染する家畜の病気です。人間が炭疽病に感染するのは通常、皮革や羊毛などの感染した動物の製品を扱ったり、感染した動物製品から炭疽菌の胞子を吸い込んだりしてです。感染した動物の肉を調理が不十分な状態で食べることでも感染することがあります。炭疽病が人から人へ感染することは知られていません。

炭疽菌感染症には 3 つの臨床的形態があります。皮膚炭疽菌感染症が最も一般的で、報告された症例の 95% 以上を占めています。皮膚炭疽菌感染症は、皮膚の擦り傷から胞子が侵入することで発生し、世界中で毎年 2,000 件発生していると推定されています。

炭疽菌の鑑別診断には、臨床的特徴に応じて、PCR、グラム染色、血液、胸水、潰瘍部位、脳脊髄液、および便からの培養などの関連検体が含まれます。利用可能な技術は多数あります。ほとんどの検査は、培養ベースの従来の方法、免疫学的検出、核酸ベースの検査、リガンドベースの検出、およびバイオセンサーのいずれかの技術を使用して、微生物全体、微生物抗原、または微生物核酸を検出することに基づいています。

ドライバー

  • 炭疽菌感染症の蔓延

細菌感染症の発生は世界中で増加しています。炭疽は、好気性グラム陽性胞子形成細菌である炭疽菌によって引き起こされる細菌感染症です。炭疽菌胞子の侵入経路に応じて、主に皮膚、肺、または胃腸の感染症として発生します。後に、特徴的な黒いかさぶた状の斑点が患部の皮膚に現れ、数週間後には緩み始め、最終的に剥がれ落ちて瘢痕を残します。これらの経過は非常に特徴的であるため、まれではありますが、この病気に精通している医師が診断を見逃すことはほとんどありません。肺炭疽は、3 種類の炭疽の中で最も致命的で、吸入された胞子が気管気管支リンパ節内で発芽して増殖します。炭疽は、人間と動物の両方に影響を与える有害な病気です。これは炭疽菌によって引き起こされる生命を脅かす感染症です。炭疽菌感染症の発生率と蔓延が増加しているため、少量の感染でも検出できる感度の高い診断アプローチの必要性が高まっています。

炭疽菌に苦しむ人々の数が世界中で増加していることは、炭疽菌治療市場の成長を牽引する主な要因の 1 つです。新しい治療法を開発する研究者への資金援助の増加、および民間人や軍隊における炭疽菌への曝露の脅威の増加が、市場の成長を加速させています。研究開発プログラムの数の増加、および革新的で効果的な治療法の新たな開発を促進するための官民パートナーシップの増加が、市場にさらなる影響を与えています。

  • 炭疽菌治療対象者に対する研究資金の増加と新しい治療法の開発

さまざまなタイプの患者を治療するための手順を変更するには、研究開発が必須条件です。炭疽菌治療の需要は、すべての国を巻き込んで世界中で高まっています。そのため、企業は患者に効果的な治療を提供することに成功するために、研究開発に継続的に注力しています。近年、診断を新たな段階に進める多くの診断アプローチが登場しており、人体中の寄生虫の最小量さえも検出できるものが多くあります。

診断におけるこれらの新しいアプローチは、市場を前進させるでしょう。研究資金の増加と炭疽菌治療のための新しい治療法の開発により、炭疽菌に対して効果的に作用するために細菌の増殖と毒素生成の両方を標的とする、いくつかの新しい抗生物質と既存の抗生物質、および有望性が高まっている毒素阻害剤があります。

企業が絶えず開発活動に取り組んでいるため、より革新的な製品が市場に投入されています。開発された新しいツールは、より短い時間間隔で細菌感染を検出する効率が高く、有効率も高いため、消費者は適切なタイミングで適切な治療を受けることができます。したがって、これは、アジア太平洋炭疽菌治療市場の成長の原動力として、研究開発の増加が期待されることを意味します。

機会

  •  上昇傾向にある製品の発売

ヒトの感染は通常、感染した動物または動物製品との接触によって起こり、皮膚、吸入、または胃腸の感染として現れることがあります。炭疽菌の世界的な発生率は一般的に増加しています。したがって、世界中でこの病気の患者数が増加しており、炭疽菌による死亡リスクを最小限に抑えるために、非常に効果的で高度な炭疽菌治療製品が求められています。さらに、先進国の医療制度は、リスク要因が少なく、高度な炭疽菌治療製品を好みます。このため、主要な市場プレーヤーは製品の発売に非常に注力しています。

このように、新製品の発売が進むと、よりよい患者体験のために、非常に効果的で先進的な医療製品が提供されます。新製品の発売は、会社への注目を集めるだけでなく、アジア太平洋市場での会社の存在感を高めます。新製品の発売の基本的な有益な要因は、会社の事業成長を加速させることです。一方、新製品の発売は会社に収益源を生み出し、新製品の発売で確立された収益源は長年にわたって持続する可能性があります。このため、新製品の発売は、炭疽菌治療市場での事業成長を高めるための市場プレーヤーにとって大きなチャンスになると予想されます。

制約/課題

  • 治療費が高い

製品のコストは市場で大きな要因となります。市場には多くの診断オプションがありますが、コストが高いため、ほとんどの人は診断を避ける傾向があります。診断アプローチの感度と特異性が向上したため、検査のコストも増加しました。手順のコストが高いのは、治療のさまざまなチェックポイントと、そのような手順を実行するためのハイテクなモダリティの使用によるものです。技術的に高度なデバイスのコストが高いため、手順のコストも比例して高くなり、手順のコストが高いため、市場の需要が妨げられると予想されます。

さらに、無症候性感染は、細菌の特定に非常に特殊な検査を受ける必要があり、費用がかかります。炭疽菌の診断費用が高いため、市場の成長が抑制されると予想されます。特定治療の費用が高すぎるため、医師と患者は高品質で効果的なソリューションを受け入れることが制限されます。今後、治療手順の高コストは、全体的な治療コストに悪影響を及ぼします。その結果、低所得国と中所得国における将来の治療需要が制限されることになります。これは、高コストの手順がアジア太平洋炭疽菌治療市場の成長を抑制すると予想されることを示唆しています。

最近の開発

  • 2022年6月、エマージェント・バイオソリューションズ社は、米国食品医薬品局(FDA)が、推奨される抗菌薬による18~65歳の人における炭疽菌への曝露が疑われる、または確認された後の疾患の曝露後予防について評価された新しい炭疽菌ワクチン候補であるAV7909の生物学的製剤承認申請(BLA)の審査を受理したことを発表しました。
  • 2022年1月、アレンビック・ファーマシューティカルズ・リミテッドは、感受性細菌が原因であることが証明されているか強く疑われる感染症の治療または予防にのみ使用されるドキシサイクリン水和物徐放錠USP、75mg、100mg、150mg、200mgの簡略新薬申請(ANDA)について、米国食品医薬品局(USFDA)から最終承認を受けたと発表しました。これにより、同社の製品ポートフォリオが拡大します。

アジア太平洋炭疽菌治療市場のセグメンテーション

アジア太平洋地域の炭疽菌治療市場は、種類、投与経路、エンドユーザーに基づいて 3 つの主要なセグメントに分類されます。セグメント間の成長は、ニッチな成長分野と市場へのアプローチ戦略を分析し、コア アプリケーション領域とターゲット市場の違いを決定するのに役立ちます。

タイプ

  • 皮膚炭疽
  • 肺炭疽病
  • 腸炭疽

タイプに基づいて、アジア太平洋炭疽菌治療市場は、皮膚炭疽菌、肺炭疽菌、腸炭疽菌に分類されます。

投与経路

  • 皮膚炭疽
  • 肺炭疽病
  • 腸炭疽

投与経路に基づいて、アジア太平洋炭疽菌治療市場は経口、非経口、その他に分類されます。

エンドユーザー

  • 政府機関
  • 病院
  • 学術研究機関、
  • その他

炭疽菌治療市場

エンドユーザーに基づいて、アジア太平洋炭疽菌治療市場は、政府機関、病院、学術研究機関、その他に分類されます。

炭疽菌治療市場の地域分析/洞察

アジア太平洋地域の炭疽菌治療市場が分析され、上記のようにタイプ、投与経路、エンドユーザー別に市場規模の洞察と傾向が提供されます。

炭疽菌治療報告書の対象国は、日本、中国、インド、韓国、オーストラリア、シンガポール、マレーシア、タイ、インドネシア、フィリピン、その他のアジア太平洋諸国です。

発展途上地域での技術進歩の進展により、中国が優位に立つことが予想されます。

レポートの国別セクションでは、市場の現在および将来の動向に影響を与える個別の市場影響要因と市場規制の変更も提供しています。下流および上流のバリュー チェーン分析、技術動向、ポーターの 5 つの力の分析、ケース スタディなどのデータ ポイントは、個々の国の市場シナリオを予測するために使用される指標の一部です。また、国別データの予測分析を提供する際には、アジア太平洋ブランドの存在と可用性、および地元および国内ブランドとの競争が激しいか少ないために直面​​する課題、国内関税と貿易ルートの影響も考慮されます。

競争環境と炭疽菌治療市場シェア分析

アジア太平洋炭疽菌治療市場の競争状況は、競合他社による詳細を提供します。含まれる詳細には、会社概要、会社の財務状況、生み出される収益、市場の可能性、研究開発への投資、新しい市場への取り組み、アジア太平洋でのプレゼンス、生産拠点と施設、生産能力、会社の強みと弱み、製品の発売、製品の幅と広さ、アプリケーションの優位性などがあります。提供された上記のデータ ポイントは、炭疽菌治療市場に対する会社の重点にのみ関連しています。

市場のプレーヤーとしては、Alembic Pharmaceuticals、Sun Pharmaceutical Industries Ltd.、Zydus Group、Bayer AG、Pfizer Inc.、EMERGENT、Sanofi、Lupin、Takeda Pharmaceutical Company Limited、Teva Pharmaceutical Industries Ltd.、ARISTO Pharmaceuticals Private Limited、INDOCO REMEDIES LTD.、GC Biopharma, corp.などが挙げられます。

研究方法

データ収集と基準年分析は、大規模なサンプル サイズのデータ​​収集モジュールを使用して行われます。市場データは、市場統計モデルとコヒーレント モデルを使用して分析および推定されます。さらに、市場シェア分析と主要トレンド分析は、市場レポートの主要な成功要因です。DBMR 調査チームが使用する主要な調査方法は、データ マイニング、データ変数の市場への影響の分析、および一次 (業界の専門家) 検証を含むデータ三角測量です。これとは別に、データ モデルには、ベンダー ポジショニング グリッド、市場タイムライン分析、市場概要とガイド、企業ポジショニング グリッド、企業市場シェア分析、測定基準、アジア太平洋と地域、ベンダー シェア分析が含まれます。さらに質問がある場合は、アナリストへの電話をリクエストしてください。


SKU-

世界初のマーケットインテリジェンスクラウドに関するレポートにオンラインでアクセスする

  • インタラクティブなデータ分析ダッシュボード
  • 成長の可能性が高い機会のための企業分析ダッシュボード
  • カスタマイズとクエリのためのリサーチアナリストアクセス
  • インタラクティブなダッシュボードによる競合分析
  • 最新ニュース、更新情報、トレンド分析
  • 包括的な競合追跡のためのベンチマーク分析のパワーを活用
デモのリクエスト

目次

1 INTRODUCTION

1.1 OBJECTIVES OF THE STUDY

1.2 MARKET DEFINITION

1.3 OVERVIEW OF THE ASIA PACIFIC ANTHRAX TREATMENT MARKET

1.4 LIMITATIONS

1.5 MARKETS COVERED

2 MARKET SEGMENTATION

2.1 MARKETS COVERED

2.2 GEOGRAPHICAL SCOPE

2.3 YEARS CONSIDERED FOR THE STUDY

2.4 CURRENCY AND PRICING

2.5 DBMR TRIPOD DATA VALIDATION MODEL

2.6 MULTIVARIATE MODELLING

2.7 PRODUCT SEGMENT LIFELINE CURVE

2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS

2.9 DBMR MARKET POSITION GRID

2.1 MARKET APPLICATION COVERAGE GRID

2.11 VENDOR SHARE ANALYSIS

2.12 SECONDARY SOURCES

2.13 ASSUMPTIONS

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

4.1 PESTEL ANALYSIS

4.2 PORTER’S FIVE FORCES

4.3 DEMOGRAPHIC TRENDS-

4.4 EPIDEMIOLOGY AND DEMOGRAPHICS-

4.4.1 INCIDENCE

4.4.2 DEVELOPED COUNTRIES-

4.4.3 DEVELOPING COUNTRIES-

4.5 PATIENT ENROLMENT STRATEGIES-

4.6 PATIENT FLOW DIAGRAM FOR ANTHRAX INFECTION-

4.7 CURRENT STATE OF ANTHRAX VACCINES

4.8 ASIA PACIFIC ANTIBIOTIC CONSUMPTION RATES INCREASED BY 46 PERCENT IN THE LAST TWO DECADES, ACCORDING TO THE FIRST STUDY TO PROVIDE LONGITUDINAL ESTIMATES FOR HUMAN ANTIBIOTIC CONSUMPTION COVERING 204 COUNTRIES FROM 2000 TO 2018.

4.9 ASIA PACIFIC ANTIBIOTIC CONSUMPTION AND PROJECTED CONSUMPTION-

5 THE M&A IN THE ANTHRAX MARKET INDICATES AN UPCOMING LONG RUN IN VACCINE DEVELOPMENT AROUND THE GLOBE. CURRENT AND SOME OF LAST YEAR’S ACQUISITION BETWEEN LEADERS AND SMALL SIZE PHARMACEUTICAL SHOWS THE CONTINUOUS DEVELOPMENT IN THE COMPANY’S PIPELINE FOR ANTHRAX TREATMENT.

6 ASIA PACIFIC ANTHRAX TREATMENT MARKET: REGULATIONS

7 MARKET OVERVIEW

7.1 DRIVERS

7.1.1 INCREASING INCIDENCE OF ANTHRAX INFECTION

7.1.2 INCREASE IN RESEARCH FUNDING AND THE DEVELOPMENT OF NOVEL THERAPIES FOR THE TREATMENT OF ANTHRAX

7.1.3 TECHNOLOGICAL ADVANCEMENTS IN TREATMENT PROCEDURE

7.1.4 STRATEGIC INITIATIVES ADOPTED BY MARKET PLAYERS

7.2 RESTRAINTS

7.2.1 HIGH COST ASSOCIATED WITH ANTHRAX DIAGNOSTIC TREATMENT

7.2.2 FALSE DATA INTERPRETATION

7.3 OPPORTUNITIES

7.3.1 RISING PRODUCT LAUNCHES

7.3.2 RISING GOVERNMENT INITIATIVES

7.3.3 IMPROVING A BETTER HEALTHCARE SYSTEM

7.4 CHALLENGES

7.4.1 LACK OF AWARENESS AMONG PEOPLE ABOUT ANTHRAX INFECTION

7.4.2 LACK OF SKILLED PROFESSIONALS

8 ASIA PACIFIC ANTHRAX TREATMENT MARKET, BY TYPE

8.1 OVERVIEW

8.2 CUTANEOUS ANTHRAX

8.2.1 ANTIBIOTICS

8.2.1.1 BY DRUGS

8.2.1.1.1 CIPROFLOXACIN

8.2.1.1.2 LEVOFLOXACIN

8.2.1.1.3 DOXYCYCLINE

8.2.1.1.4 AMPICILLIN

8.2.1.1.5 OTHERS

8.2.1.2 BY PRODUCT TYPES

8.2.1.2.1 GENERICS

8.2.1.2.2 BRANDED

8.2.1.2.2.1 CIPRO

8.2.1.2.2.2 LEVO

8.2.1.2.2.3 DOXY

8.2.1.2.2.4 AMPICI

8.2.1.2.2.5 OTHERS

8.2.2 ANTITOXINS

8.2.2.1 RAXIBACUMAB

8.2.2.2 OBILTOXAXIMAB (ANTHIM)

8.2.2.3 ANTHRACIL (ANTHRAX IMMUNE GLOBULIN INTRAVENOUS)

8.2.2.4 OTHERS

8.2.3 VACCINES

8.2.3.1 RAXIBACUMAB

8.2.4 SURGERY

8.3 PULMONARY ANTHRAX

8.3.1 ANTIBIOTICS

8.3.1.1 BY DRUGS

8.3.1.1.1 CIPROFLOXACIN

8.3.1.1.2 LEVOFLOXACIN

8.3.1.1.3 DOXYCYCLINE

8.3.1.1.4 AMPICILLIN

8.3.1.1.5 OTHERS

8.3.1.2 BY PRODUCT TYPES

8.3.1.2.1 GENERICS

8.3.1.2.2 BRANDED

8.3.1.2.2.1 CIPRO

8.3.1.2.2.2 LEVO

8.3.1.2.2.3 DOXY

8.3.1.2.2.4 AMPICI

8.3.1.2.2.5 OTHERS

8.3.2 ANTITOXINS

8.3.2.1 RAXIBACUMAB

8.3.2.2 OBILTOXAXIMAB (ANTHIM)

8.3.2.3 ANTHRACIL (ANTHRAX IMMUNE GLOBULIN INTRAVENOUS)

8.3.2.4 OTHERS

8.3.3 VACCINES

8.3.3.1 RAXIBACUMAB

8.3.3.2 SURGERY

8.4 INTESTINAL ANTHRAX

8.4.1 ANTIBIOTICS

8.4.1.1 BY DRUGS

8.4.1.1.1 CIPROFLOXACIN

8.4.1.1.2 LEVOFLOXACIN

8.4.1.1.3 DOXYCYCLINE

8.4.1.1.4 AMPICILLIN

8.4.1.1.5 OTHERS

8.4.1.2 BY PRODUCT TYPES

8.4.1.2.1 GENERICS

8.4.1.2.2 BRANDED

8.4.1.2.2.1 CIPRO

8.4.1.2.2.2 LEVO

8.4.1.2.2.3 DOXY

8.4.1.2.2.4 AMPICI

8.4.1.2.2.5 OTHERS

8.4.2 ANTITOXINS

8.4.2.1 RAXIBACUMAB

8.4.2.2 OBILTOXAXIMAB (ANTHIM)

8.4.2.3 ANTHRACIL (ANTHRAX IMMUNE GLOBULIN INTRAVENOUS)

8.4.2.4 OTHERS

8.4.3 VACCINES

8.4.3.1 RAXIBACUMAB

8.4.3.2 SURGERY

9 ASIA PACIFIC ANTHRAX TREATMENT MARKET, BY ROUTE OF ADMINISTRATION

9.1 OVERVIEW

9.2 PARENTERAL

9.3 ORAL

9.4 OTHERS

10 ASIA PACIFIC ANTHRAX TREATMENT MARKET, BY END USER

10.1 OVERVIEW

10.2 GOVERNMENT ORGANIZATION

10.3 HOSPITALS

10.4 ACADEMIC AND RESEARCH

10.5 OTHERS

11 ASIA PACIFIC VIRTUAL REALITY MARKET, BY GEOGRAPHY

11.1 ASIA-PACIFIC

11.1.1 CHINA

11.1.2 JAPAN

11.1.3 SOUTH KOREA

11.1.4 INDIA

11.1.5 AUSTRALIA

11.1.6 SINGAPORE

11.1.7 THAILAND

11.1.8 MALAYSIA

11.1.9 INDONESIA

11.1.10 PHILIPPINES

11.1.11 REST OF ASIA-PACIFIC

12 ASIA PACIFIC ANTHRAX TREATMENT MARKET, COMPANY LANDSCAPE

12.1 COMPANY SHARE ANALYSIS: ASIA PACIFIC

13 SWOT ANALYSIS

14 COMPANY PROFILE

14.1 BAYER AG

14.1.1 COMPANY SNAPSHOT

14.1.2 REVENUE ANALYSIS

14.1.3 COMPANY SHARE ANALYSIS

14.1.4 PRODUCT PORTFOLIO

14.1.5 RECENT DEVELOPMENTS

14.2 PFIZER INC.

14.2.1 COMPANY SNAPSHOT

14.2.2 REVENUE ANALYSIS

14.2.3 COMPANY SHARE ANALYSIS

14.2.4 PRODUCT PORTFOLIO

14.2.5 RECENT DEVELOPMENTS

14.3 TEVA PHARMACEUTICAL INDUSTRIES LTD

14.3.1 COMPANY SNAPSHOT

14.3.2 REVENUE ANALYSIS

14.3.3 COMPANY SHARE ANALYSIS

14.3.4 PRODUCT PORTFOLIO

14.3.5 RECENT DEVELOPMENT

14.4 SANOFI

14.4.1 COMPANY SNAPSHOT

14.4.2 REVENUE ANALYSIS

14.4.3 COMPANY SHARE ANALYSIS

14.4.4 PRODUCT PORTFOLIO

14.4.5 RECENT DEVELOPMENTS

14.5 TAKEDA PHARMACEUTICAL COMPANY LIMITED.

14.5.1 COMPANY SNAPSHOT

14.5.2 REVENUE ANALYSIS

14.5.3 PRODUCT PORTFOLIO

14.5.4 RECENT DEVELOPMENT

14.6 ALEMBIC PHARMACEUTICALS LIMITED

14.6.1 COMPANY SNAPSHOT

14.6.2 PRODUCT PORTFOLIO

14.6.3 RECENT DEVELOPMENTS

14.7 ALTIMMUNE

14.7.1 COMPANY SNAPSHOT

14.7.2 REVENUE ANALYSIS

14.7.3 PRODUCT PORTFOLIO

14.7.4 RECENT DEVELOPMENTS

14.8 ARISTO PHARMACEUTICALS PRIVATE LIMITED

14.8.1 COMPANY SNAPSHOT

14.8.2 PRODUCT PORTFOLIO

14.8.3 RECENT DEVELOPMENTS

14.9 BLUEWILLOW BIOLOGICS.

14.9.1 COMPANY SNAPSHOT

14.9.2 PRODUCT PORTFOLIO

14.9.3 RECENT DEVELOPMENTS

14.1 DEINOVE

14.10.1 COMPANY SNAPSHOT

14.10.2 REVENUE ANALYSIS

14.10.3 PRODUCT PORTFOLIO

14.10.4 RECENT DEVELOPMENTS

14.11 EMERGENT

14.11.1 COMPANY SNAPSHOT

14.11.2 REVENUE ANALYSIS

14.11.3 PRODUCT PORTFOLIO

14.11.4 RECENT DEVELOPMENTS

14.12 ELUSYS THERAPEUTICS INC.

14.12.1 COMPANY SNAPSHOT

14.12.2 PRODUCT PORTFOLIO

14.12.3 RECENT DEVELOPMENTS

14.13 GC BIOPHARMA CORP.

14.13.1 COMPANY SNAPSHOT

14.13.2 REVENUE ANALYSIS

14.13.3 PRODUCT PORTFOLIO

14.13.4 RECENT DEVELOPMENTS

14.14 INDOCO REMEDIES LTD.

14.14.1 COMPANY SNAPSHOT

14.14.2 REVENUE ANALYSIS

14.14.3 PRODUCT PORTFOLIO

14.14.4 RECENT DEVELOPMENTS

14.15 INTEGRATED BIOTHERAPEUTICS, INC.

14.15.1 COMPANY SNAPSHOT

14.15.2 PRODUCT PORTFOLIO

14.15.3 RECENT DEVELOPMENTS

14.16 LUPIN.

14.16.1 COMPANY SNAPSHOT

14.16.2 REVENUE ANALYSIS

14.16.3 PRODUCT PORTFOLIO

14.16.4 RECENT DEVELOPMENTS

14.17 PARATEK PHARMACEUTICALS, INC.

14.17.1 COMPANY SNAPSHOT

14.17.2 REVENUE ANALYSIS

14.17.3 PRODUCT PORTFOLIO

14.17.4 RECENT DEVELOPMENTS

14.18 PORTON BIOPHARMA

14.18.1 COMPANY SNAPSHOT

14.18.2 PRODUCT PORTFOLIO

14.18.3 RECENT DEVELOPMENTS

14.19 SOLIGENIX

14.19.1 COMPANY SNAPSHOT

14.19.2 REVENUE ANALYSIS

14.19.3 PRODUCT PORTFOLIO

14.19.4 RECENT DEVELOPMENTS

14.2 SUN PHARMACEUTICAL INDUSTRIES LTD.

14.20.1 COMPANY SNAPSHOT

14.20.2 REVENUE ANALYSIS

14.20.3 PRODUCT PORTFOLIO

14.20.4 RECENT DEVELOPMENTS

14.21 ZYDUS GROUP

14.21.1 COMPANY SNAPSHOT

14.21.2 REVENUE ANALYSIS

14.21.3 PRODUCT PORTFOLIO

14.21.4 RECENT DEVELOPMENTS

15 QUESTIONNAIRE

16 RELATED REPORTS

表のリスト

TABLE 1 POPULATION AT RISK (IN MILLIONS) BY REGION, LAND USE AND OCCUPATIONAL EXPOSURE, 2020-

TABLE 2 VACCINES IN DEVELOPMENT

TABLE 3 ANTIBIOTIC CONSUMPTION ESTIMATES BY GBD SUPER-REGION AND GBD REGION, FOR THE YEAR 2018-

TABLE 4 COUNTRY DATA OF ANTIBIOTICS CONSUMPTION-

TABLE 5 RECENT M&A IN ANTHRAX MARKET-

TABLE 6 ANTIBIOTICS MEDICINES

TABLE 7 FDA REQUIRES THE FOLLOWING SCENARIO BEFORE A DRUG IS APPROVED

TABLE 8 ASIA PACIFIC ANTHRAX TREATMENT MARKET, TYPE, 2020-2029 (USD MILLION)

TABLE 9 ASIA PACIFIC CUTANEOUS ANTHRAX IN ANTHRAX TREATMENT MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 10 ASIA PACIFIC CUTANEOUS ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 11 ASIA PACIFIC ANTIBIOTICS IN ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 12 ASIA PACIFIC BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 13 ASIA PACIFIC BY PRODUCT TYPES ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 14 ASIA PACIFIC BRANDED IN ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 15 ASIA PACIFIC ANTITOXIN IN ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 16 ASIA PACIFIC VACCINES IN ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 17 ASIA PACIFIC PULMONARY ANTHRAX IN ANTHRAX TREATMENT MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 18 ASIA PACIFIC PULMONARY ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 19 ASIA PACIFIC ANTIBIOTICS IN ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 20 ASIA PACIFIC BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 21 ASIA PACIFIC BY PRODUCT TYPES ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 22 ASIA PACIFIC BRANDED IN ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 23 ASIA PACIFIC ANTITOXIN IN ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 24 ASIA PACIFIC VACCINES IN ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 25 ASIA PACIFIC INTESTINAL ANTHRAX IN ANTHRAX TREATMENT MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 26 ASIA PACIFIC INTESTINAL ANTHRAX IN ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 27 ASIA PACIFIC ANTIBIOTICS IN ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 28 ASIA PACIFIC BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 29 ASIA PACIFIC BY PRODUCT TYPES ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 30 ASIA PACIFIC BRANDED IN ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 31 ASIA PACIFIC ANTITOXIN IN ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 32 ASIA PACIFIC VACCINES IN ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 33 ASIA PACIFIC ANTHRAX TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 34 ASIA PACIFIC PARENTERAL IN ANTHRAX TREATMENT MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 35 ASIA PACIFIC ORAL IN ANTHRAX TREATMENT MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 36 ASIA PACIFIC OTHERS IN ANTHRAX TREATMENT MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 37 ASIA PACIFIC ANTHRAX TREATMENT MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 38 ASIA PACIFIC GOVERNMENT ORGANIZATION IN ANTHRAX TREATMENT MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 39 ASIA PACIFIC HOSPITALS IN ANTHRAX TREATMENT MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 40 ASIA PACIFIC ACADEMIC AND RESEARCH IN ANTHRAX TREATMENT MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 41 ASIA PACIFIC OTHERS IN ANTHRAX TREATMENT MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 42 ASIA-PACIFIC ANTHRAX TREATMENT MARKET, BY COUNTRY, 2020-2029 (USD MILLION)

TABLE 43 ASIA-PACIFIC ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 44 ASIA-PACIFIC CUTANEOUS ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 45 ASIA-PACIFIC ANTIBIOTICS ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 46 ASIA-PACIFIC BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 47 ASIA-PACIFIC BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (UNITS)

TABLE 48 ASIA-PACIFIC BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (ASP)

TABLE 49 ASIA-PACIFIC BY PRODUCT TYPE ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 50 ASIA-PACIFIC BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 51 ASIA-PACIFIC BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (UNITS)

TABLE 52 ASIA-PACIFIC BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (UNITS)

TABLE 53 ASIA-PACIFIC ANTITOXIN ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 54 ASIA-PACIFIC BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (UNITS)

TABLE 55 ASIA-PACIFIC BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (ASP)

TABLE 56 ASIA-PACIFIC VACCINE ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 57 ASIA-PACIFIC BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (UNITS)

TABLE 58 ASIA-PACIFIC BRANDED TYPES ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (ASP)

TABLE 59 ASIA-PACIFIC PULMONARY ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 60 ASIA-PACIFIC ANTIBIOTICS ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 61 ASIA-PACIFIC BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 62 ASIA-PACIFIC BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (UNITS)

TABLE 63 ASIA-PACIFIC BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (ASP)

TABLE 64 ASIA-PACIFIC BY PRODUCT TYPE ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 65 ASIA-PACIFIC BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 66 ASIA-PACIFIC BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (UNITS)

TABLE 67 ASIA-PACIFIC BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (UNITS)

TABLE 68 ASIA-PACIFIC ANTITOXIN ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 69 ASIA-PACIFIC BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (UNITS)

TABLE 70 ASIA-PACIFIC BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (ASP)

TABLE 71 ASIA-PACIFIC VACCINE ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 72 ASIA-PACIFIC BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (UNITS)

TABLE 73 ASIA-PACIFIC BRANDED TYPES ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (ASP)

TABLE 74 ASIA-PACIFIC INTESTINAL ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 75 ASIA-PACIFIC ANTIBIOTICS ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 76 ASIA-PACIFIC BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 77 ASIA-PACIFIC BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (UNITS)

TABLE 78 ASIA-PACIFIC BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (ASP)

TABLE 79 ASIA-PACIFIC BY PRODUCT TYPE ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 80 ASIA-PACIFIC BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 81 ASIA-PACIFIC BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (UNITS)

TABLE 82 ASIA-PACIFIC BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (UNITS)

TABLE 83 ASIA-PACIFIC ANTITOXIN ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 84 ASIA-PACIFIC BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (UNITS)

TABLE 85 ASIA-PACIFIC BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (ASP)

TABLE 86 ASIA-PACIFIC VACCINE ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 87 ASIA-PACIFIC BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (UNITS)

TABLE 88 ASIA-PACIFIC BRANDED TYPES ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (ASP)

TABLE 89 ASIA-PACIFIC ANTHRAX TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 90 ASIA-PACIFIC ANTHRAX TREATMENT MARKET, BY END USERS, 2020-2029 (USD MILLION)

TABLE 91 CHINA ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 92 CHINA CUTANEOUS ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 93 CHINA ANTIBIOTICS ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 94 CHINA BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 95 CHINA BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (UNITS)

TABLE 96 CHINA BY PRODUCT TYPE ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 97 CHINA BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 98 CHINA BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (UNITS)

TABLE 99 CHINA ANTITOXIN ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 100 CHINA BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (UNITS)

TABLE 101 CHINA VACCINE ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 102 CHINA BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (UNITS)

TABLE 103 CHINA PULMONARY ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 104 CHINA ANTIBIOTICS ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 105 CHINA BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 106 CHINA BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (UNITS)

TABLE 107 CHINA BY PRODUCT TYPE ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 108 CHINA BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 109 CHINA BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (UNITS)

TABLE 110 CHINA ANTITOXIN ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 111 CHINA BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (UNITS)

TABLE 112 CHINA VACCINE ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 113 CHINA BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (UNITS)

TABLE 114 CHINA INTESTINAL ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 115 CHINA ANTIBIOTICS ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 116 CHINA BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 117 CHINA BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (UNITS)

TABLE 118 CHINA BY PRODUCT TYPE ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 119 CHINA BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 120 CHINA BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (UNITS)

TABLE 121 CHINA ANTITOXIN ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 122 CHINA BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (UNITS)

TABLE 123 CHINA VACCINE ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 124 CHINA BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (UNITS)

TABLE 125 CHINA ANTHRAX TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 126 CHINA ANTHRAX TREATMENT MARKET, BY END USERS, 2020-2029 (USD MILLION)

TABLE 127 JAPAN ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 128 JAPAN CUTANEOUS ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 129 JAPAN ANTIBIOTICS ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 130 JAPAN BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 131 JAPAN BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (UNITS)

TABLE 132 JAPAN BY PRODUCT TYPE ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 133 JAPAN BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 134 JAPAN BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (UNITS)

TABLE 135 JAPAN ANTITOXIN ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 136 JAPAN BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (UNITS)

TABLE 137 JAPAN VACCINE ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 138 JAPAN BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (UNITS)

TABLE 139 JAPAN PULMONARY ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 140 JAPAN ANTIBIOTICS ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 141 JAPAN BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 142 JAPAN BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (UNITS)

TABLE 143 JAPAN BY PRODUCT TYPE ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 144 JAPAN BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 145 JAPAN BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (UNITS)

TABLE 146 JAPAN ANTITOXIN ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 147 JAPAN BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (UNITS)

TABLE 148 JAPAN VACCINE ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 149 JAPAN BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (UNITS)

TABLE 150 JAPAN INTESTINAL ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 151 JAPAN ANTIBIOTICS ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 152 JAPAN BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 153 JAPAN BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (UNITS)

TABLE 154 JAPAN BY PRODUCT TYPE ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 155 JAPAN BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 156 JAPAN BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (UNITS)

TABLE 157 JAPAN ANTITOXIN ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 158 JAPAN BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (UNITS)

TABLE 159 JAPAN VACCINE ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 160 JAPAN BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (UNITS)

TABLE 161 JAPAN ANTHRAX TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 162 JAPAN ANTHRAX TREATMENT MARKET, BY END USERS, 2020-2029 (USD MILLION)

TABLE 163 SOUTH KOREA ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 164 SOUTH KOREA CUTANEOUS ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 165 SOUTH KOREA ANTIBIOTICS ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 166 SOUTH KOREA BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 167 SOUTH KOREA BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (UNITS)

TABLE 168 SOUTH KOREA BY PRODUCT TYPE ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 169 SOUTH KOREA BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 170 SOUTH KOREA BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (UNITS)

TABLE 171 SOUTH KOREA ANTITOXIN ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 172 SOUTH KOREA BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (UNITS)

TABLE 173 SOUTH KOREA VACCINE ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 174 SOUTH KOREA BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (UNITS)

TABLE 175 SOUTH KOREA PULMONARY ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 176 SOUTH KOREA ANTIBIOTICS ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 177 SOUTH KOREA BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 178 SOUTH KOREA BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (UNITS)

TABLE 179 SOUTH KOREA BY PRODUCT TYPE ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 180 SOUTH KOREA BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 181 SOUTH KOREA BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (UNITS)

TABLE 182 SOUTH KOREA ANTITOXIN ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 183 SOUTH KOREA BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (UNITS)

TABLE 184 SOUTH KOREA VACCINE ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 185 SOUTH KOREA BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (UNITS)

TABLE 186 SOUTH KOREA INTESTINAL ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 187 SOUTH KOREA ANTIBIOTICS ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 188 SOUTH KOREA BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 189 SOUTH KOREA BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (UNITS)

TABLE 190 SOUTH KOREA BY PRODUCT TYPE ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 191 SOUTH KOREA BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 192 SOUTH KOREA BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (UNITS)

TABLE 193 SOUTH KOREA ANTITOXIN ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 194 SOUTH KOREA BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (UNITS)

TABLE 195 SOUTH KOREA VACCINE ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 196 SOUTH KOREA BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (UNITS)

TABLE 197 SOUTH KOREA ANTHRAX TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 198 SOUTH KOREA ANTHRAX TREATMENT MARKET, BY END USERS, 2020-2029 (USD MILLION)

TABLE 199 INDIA ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 200 INDIA CUTANEOUS ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 201 INDIA ANTIBIOTICS ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 202 INDIA BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 203 INDIA BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (UNITS)

TABLE 204 INDIA BY PRODUCT TYPE ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 205 INDIA BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 206 INDIA BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (UNITS)

TABLE 207 INDIA ANTITOXIN ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 208 INDIA BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (UNITS)

TABLE 209 INDIA VACCINE ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 210 INDIA BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (UNITS)

TABLE 211 INDIA PULMONARY ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 212 INDIA ANTIBIOTICS ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 213 INDIA BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 214 INDIA BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (UNITS)

TABLE 215 INDIA BY PRODUCT TYPE ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 216 INDIA BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 217 INDIA BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (UNITS)

TABLE 218 INDIA ANTITOXIN ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 219 INDIA BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (UNITS)

TABLE 220 INDIA VACCINE ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 221 INDIA BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (UNITS)

TABLE 222 INDIA INTESTINAL ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 223 INDIA ANTIBIOTICS ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 224 INDIA BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 225 INDIA BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (UNITS)

TABLE 226 INDIA BY PRODUCT TYPE ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 227 INDIA BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 228 INDIA BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (UNITS)

TABLE 229 INDIA ANTITOXIN ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 230 INDIA BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (UNITS)

TABLE 231 INDIA VACCINE ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 232 INDIA BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (UNITS)

TABLE 233 INDIA ANTHRAX TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 234 INDIA ANTHRAX TREATMENT MARKET, BY END USERS, 2020-2029 (USD MILLION)

TABLE 235 AUSTRALIA ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 236 AUSTRALIA CUTANEOUS ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 237 AUSTRALIA ANTIBIOTICS ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 238 AUSTRALIA BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 239 AUSTRALIA BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (UNITS)

TABLE 240 AUSTRALIA BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (ASP)

TABLE 241 AUSTRALIA BY PRODUCT TYPE ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 242 AUSTRALIA BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 243 AUSTRALIA BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (UNITS)

TABLE 244 AUSTRALIA ANTITOXIN ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 245 AUSTRALIA BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (UNITS)

TABLE 246 AUSTRALIA VACCINE ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 247 AUSTRALIA BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (UNITS)

TABLE 248 AUSTRALIA BRANDED TYPES ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (ASP)

TABLE 249 AUSTRALIA PULMONARY ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 250 AUSTRALIA ANTIBIOTICS ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 251 AUSTRALIA BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 252 AUSTRALIA BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (UNITS)

TABLE 253 AUSTRALIA BY PRODUCT TYPE ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 254 AUSTRALIA BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 255 AUSTRALIA BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (UNITS)

TABLE 256 AUSTRALIA ANTITOXIN ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 257 AUSTRALIA BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (UNITS)

TABLE 258 AUSTRALIA VACCINE ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 259 AUSTRALIA BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (UNITS)

TABLE 260 AUSTRALIA INTESTINAL ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 261 AUSTRALIA ANTIBIOTICS ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 262 AUSTRALIA BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 263 AUSTRALIA BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (UNITS)

TABLE 264 AUSTRALIA BY PRODUCT TYPE ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 265 AUSTRALIA BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 266 AUSTRALIA BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (UNITS)

TABLE 267 AUSTRALIA ANTITOXIN ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 268 AUSTRALIA BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (ASP)

TABLE 269 AUSTRALIA VACCINE ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 270 AUSTRALIA BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (UNITS)

TABLE 271 AUSTRALIA ANTHRAX TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 272 AUSTRALIA ANTHRAX TREATMENT MARKET, BY END USERS, 2020-2029 (USD MILLION)

TABLE 273 SINGAPORE ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 274 SINGAPORE CUTANEOUS ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 275 SINGAPORE ANTIBIOTICS ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 276 SINGAPORE BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 277 SINGAPORE BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (UNITS)

TABLE 278 SINGAPORE BY PRODUCT TYPE ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 279 SINGAPORE BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 280 SINGAPORE BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (UNITS)

TABLE 281 SINGAPORE ANTITOXIN ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 282 SINGAPORE BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (UNITS)

TABLE 283 SINGAPORE VACCINE ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 284 SINGAPORE BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (UNITS)

TABLE 285 SINGAPORE PULMONARY ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 286 SINGAPORE ANTIBIOTICS ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 287 SINGAPORE BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 288 SINGAPORE BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (UNITS)

TABLE 289 SINGAPORE BY PRODUCT TYPE ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 290 SINGAPORE BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 291 SINGAPORE BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (UNITS)

TABLE 292 SINGAPORE ANTITOXIN ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 293 SINGAPORE BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (UNITS)

TABLE 294 SINGAPORE VACCINE ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 295 SINGAPORE BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (UNITS)

TABLE 296 SINGAPORE INTESTINAL ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 297 SINGAPORE ANTIBIOTICS ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 298 SINGAPORE BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 299 SINGAPORE BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (UNITS)

TABLE 300 SINGAPORE BY PRODUCT TYPE ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 301 SINGAPORE BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 302 SINGAPORE BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (UNITS)

TABLE 303 SINGAPORE ANTITOXIN ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 304 SINGAPORE BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (UNITS)

TABLE 305 SINGAPORE VACCINE ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 306 SINGAPORE BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (UNITS)

TABLE 307 SINGAPORE ANTHRAX TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 308 SINGAPORE ANTHRAX TREATMENT MARKET, BY END USERS, 2020-2029 (USD MILLION)

TABLE 309 THAILAND ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 310 THAILAND CUTANEOUS ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 311 THAILAND ANTIBIOTICS ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 312 THAILAND BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 313 THAILAND BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (UNITS)

TABLE 314 THAILAND BY PRODUCT TYPE ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 315 THAILAND BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 316 THAILAND BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (UNITS)

TABLE 317 THAILAND ANTITOXIN ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 318 THAILAND BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (UNITS)

TABLE 319 THAILAND VACCINE ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 320 THAILAND BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (UNITS)

TABLE 321 THAILAND PULMONARY ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 322 THAILAND ANTIBIOTICS ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 323 THAILAND BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 324 THAILAND BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (UNITS)

TABLE 325 THAILAND BY PRODUCT TYPE ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 326 THAILAND BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 327 THAILAND BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (UNITS)

TABLE 328 THAILAND ANTITOXIN ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 329 THAILAND BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (UNITS)

TABLE 330 THAILAND VACCINE ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 331 THAILAND BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (UNITS)

TABLE 332 THAILAND INTESTINAL ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 333 THAILAND ANTIBIOTICS ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 334 THAILAND BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 335 THAILAND BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (UNITS)

TABLE 336 THAILAND BY PRODUCT TYPE ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 337 THAILAND BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 338 THAILAND BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (UNITS)

TABLE 339 THAILAND ANTITOXIN ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 340 THAILAND BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (UNITS)

TABLE 341 THAILAND VACCINE ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 342 THAILAND BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (UNITS)

TABLE 343 THAILAND ANTHRAX TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 344 THAILAND ANTHRAX TREATMENT MARKET, BY END USERS, 2020-2029 (USD MILLION)

TABLE 345 MALAYSIA ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 346 MALAYSIA CUTANEOUS ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 347 MALAYSIA ANTIBIOTICS ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 348 MALAYSIA BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 349 MALAYSIA BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (UNITS)

TABLE 350 MALAYSIA BY PRODUCT TYPE ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 351 MALAYSIA BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 352 MALAYSIA BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (UNITS)

TABLE 353 MALAYSIA ANTITOXIN ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 354 MALAYSIA BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (UNITS)

TABLE 355 MALAYSIA VACCINE ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 356 MALAYSIA BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (UNITS)

TABLE 357 MALAYSIA PULMONARY ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 358 MALAYSIA ANTIBIOTICS ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 359 MALAYSIA BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 360 MALAYSIA BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (UNITS)

TABLE 361 MALAYSIA BY PRODUCT TYPE ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 362 MALAYSIA BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 363 MALAYSIA BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (UNITS)

TABLE 364 MALAYSIA ANTITOXIN ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 365 MALAYSIA BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (UNITS)

TABLE 366 MALAYSIA VACCINE ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 367 MALAYSIA BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (UNITS)

TABLE 368 MALAYSIA INTESTINAL ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 369 MALAYSIA ANTIBIOTICS ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 370 MALAYSIA BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 371 MALAYSIA BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (UNITS)

TABLE 372 MALAYSIA BY PRODUCT TYPE ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 373 MALAYSIA BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 374 MALAYSIA BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (UNITS)

TABLE 375 MALAYSIA ANTITOXIN ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 376 MALAYSIA BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (UNITS)

TABLE 377 MALAYSIA VACCINE ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 378 MALAYSIA BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (UNITS)

TABLE 379 MALAYSIA ANTHRAX TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 380 MALAYSIA ANTHRAX TREATMENT MARKET, BY END USERS, 2020-2029 (USD MILLION)

TABLE 381 INDONESIA ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 382 INDONESIA CUTANEOUS ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 383 INDONESIA ANTIBIOTICS ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 384 INDONESIA BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 385 INDONESIA BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (UNITS)

TABLE 386 INDONESIA BY PRODUCT TYPE ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 387 INDONESIA BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 388 INDONESIA BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (UNITS)

TABLE 389 INDONESIA ANTITOXIN ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 390 INDONESIA BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (UNITS)

TABLE 391 INDONESIA VACCINE ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 392 INDONESIA BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (UNITS)

TABLE 393 INDONESIA PULMONARY ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 394 INDONESIA ANTIBIOTICS ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 395 INDONESIA BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 396 INDONESIA BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (UNITS)

TABLE 397 INDONESIA BY PRODUCT TYPE ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 398 INDONESIA BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 399 INDONESIA BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (UNITS)

TABLE 400 INDONESIA ANTITOXIN ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 401 INDONESIA BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (UNITS)

TABLE 402 INDONESIA VACCINE ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 403 INDONESIA BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (UNITS)

TABLE 404 INDONESIA INTESTINAL ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 405 INDONESIA ANTIBIOTICS ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 406 INDONESIA BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 407 INDONESIA BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (UNITS)

TABLE 408 INDONESIA BY PRODUCT TYPE ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 409 INDONESIA BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 410 INDONESIA BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (UNITS)

TABLE 411 INDONESIA BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (UNITS)

TABLE 412 INDONESIA ANTITOXIN ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 413 INDONESIA BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (UNITS)

TABLE 414 INDONESIA VACCINE ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 415 INDONESIA BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (UNITS)

TABLE 416 INDONESIA ANTHRAX TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 417 INDONESIA ANTHRAX TREATMENT MARKET, BY END USERS, 2020-2029 (USD MILLION)

TABLE 418 PHILIPPINES ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 419 PHILIPPINES CUTANEOUS ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 420 PHILIPPINES ANTIBIOTICS ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 421 PHILIPPINES BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 422 PHILIPPINES BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (UNITS)

TABLE 423 PHILIPPINES BY PRODUCT TYPE ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 424 PHILIPPINES BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 425 PHILIPPINES BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (UNITS)

TABLE 426 PHILIPPINES ANTITOXIN ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 427 PHILIPPINES BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (UNITS)

TABLE 428 PHILIPPINES VACCINE ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 429 PHILIPPINES BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (UNITS)

TABLE 430 PHILIPPINES PULMONARY ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 431 PHILIPPINES ANTIBIOTICS ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 432 PHILIPPINES BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 433 PHILIPPINES BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (UNITS)

TABLE 434 PHILIPPINES BY PRODUCT TYPE ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 435 PHILIPPINES BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 436 PHILIPPINES BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (UNITS)

TABLE 437 PHILIPPINES ANTITOXIN ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 438 PHILIPPINES BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (UNITS)

TABLE 439 PHILIPPINES VACCINE ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 440 PHILIPPINES BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (UNITS)

TABLE 441 PHILIPPINES INTESTINAL ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 442 PHILIPPINES ANTIBIOTICS ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 443 PHILIPPINES BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 444 PHILIPPINES BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (UNITS)

TABLE 445 PHILIPPINES BY PRODUCT TYPE ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 446 PHILIPPINES BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 447 PHILIPPINES BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (UNITS)

TABLE 448 PHILIPPINES ANTITOXIN ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 449 PHILIPPINES BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (UNITS)

TABLE 450 PHILIPPINES VACCINE ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 451 PHILIPPINES BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (UNITS)

TABLE 452 PHILIPPINES ANTHRAX TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 453 PHILIPPINES ANTHRAX TREATMENT MARKET, BY END USERS, 2020-2029 (USD MILLION)

TABLE 454 REST OF ASIA-PACIFIC ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)

図表一覧

FIGURE 1 ASIA PACIFIC ANTHRAX TREATMENT MARKET: SEGMENTATION

FIGURE 2 ASIA PACIFIC ANTHRAX TREATMENT MARKET: DATA TRIANGULATION

FIGURE 3 ASIA PACIFIC ANTHRAX TREATMENT MARKET: DROC ANALYSIS

FIGURE 4 ASIA PACIFIC ANTHRAX TREATMENT MARKET: REGIONAL VS COUNTRY MARKET ANALYSIS

FIGURE 5 ASIA PACIFIC ANTHRAX TREATMENT MARKET: COMPANY RESEARCH ANALYSIS

FIGURE 6 ASIA PACIFIC ANTHRAX TREATMENT MARKET: INTERVIEW DEMOGRAPHICS

FIGURE 7 ASIA PACIFIC ANTHRAX TREATMENT MARKET: DBMR MARKET POSITION GRID

FIGURE 8 ASIA PACIFIC ANTHRAX TREATMENT MARKET: MARKET APPLICATION COVERAGE GRID

FIGURE 9 ASIA PACIFIC ANTHRAX TREATMENT MARKET: VENDOR SHARE ANALYSIS

FIGURE 10 ASIA PACIFIC ANTHRAX TREATMENT MARKET: SEGMENTATION

FIGURE 11 MIDDLE EAST & AFRICA IS ANTICIPATED TO DOMINATE THE ANTHRAX TREATMENT MARKET AND GROW WITH THE HIGHEST CAGR IN THE FORECAST PERIOD OF 2022 TO 2029

FIGURE 12 INCREASING INCIDENCE AND PREVALENCE OF ANTHRAX INFECTIONS ARE EXPECTED TO DRIVE THE ASIA PACIFIC ANTHRAX TREATMENT MARKET IN THE FORECAST PERIOD

FIGURE 13 TYPE SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE ASIA PACIFIC ANTHRAX TREATMENT MARKET IN 2022 & 2029

FIGURE 14 ASIA PACIFIC DISTRIBUTION OF OUTBREAKS BY COUNTRY AND GEOGRAPHIC LOCATIONS OF ANTHRAX EVENTS-

FIGURE 15 PATHOPHYSIOLOGY OF ANTHRAX-

FIGURE 16 FLOW CHART FOR SUSPECTED ANTHRAX EXPOSURE-

FIGURE 17 GC BIOPHARMA ANTHRAX CANDIDATE GC1109 IS IN PHASE 2 (NCT01624532).

FIGURE 18 BA-ISTAB IS A FUSION OF A B. ANTHRACIS SPECIFIC CWT WITH A POTENT MONOCLONAL ANTIBODY THAT NEUTRALIZE ANTHRAX TOXIN (PA).

FIGURE 19 TWO ROUTES BY WHICH VACCINATION CAN REDUCE INCIDENCE OF AMR-

FIGURE 20 DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES OF ASIA PACIFIC ANTHRAX TREATMENT MARKET

FIGURE 21 ASIA PACIFIC ANTHRAX TREATMENT MARKET : TYPE, 2021

FIGURE 22 ASIA PACIFIC ANTHRAX TREATMENT MARKET : TYPE, 2022-2029 (USD MILLION)

FIGURE 23 ASIA PACIFIC ANTHRAX TREATMENT MARKET : TYPE, CAGR (2022-2029)

FIGURE 24 ASIA PACIFIC ANTHRAX TREATMENT MARKET : TYPE, LIFELINE CURVE

FIGURE 25 ASIA PACIFIC ANTHRAX TREATMENT MARKET : BY ROUTE OF ADMINISTRATION, 2021

FIGURE 26 ASIA PACIFIC ANTHRAX TREATMENT MARKET : BY ROUTE OF ADMINISTRATION, 2022-2029 (USD MILLION)

FIGURE 27 ASIA PACIFIC ANTHRAX TREATMENT MARKET : BY ROUTE OF ADMINISTRATION, CAGR (2022-2029)

FIGURE 28 ASIA PACIFIC ANTHRAX TREATMENT MARKET : BY ROUTE OF ADMINISTRATION, LIFELINE CURVE

FIGURE 29 ASIA PACIFIC ANTHRAX TREATMENT MARKET : BY END USER, 2021

FIGURE 30 ASIA PACIFIC ANTHRAX TREATMENT MARKET : BY END USER, 2022-2029 (USD MILLION)

FIGURE 31 ASIA PACIFIC ANTHRAX TREATMENT MARKET : BY END USER, CAGR (2022-2029)

FIGURE 32 ASIA PACIFIC ANTHRAX TREATMENT MARKET : BY END USER, LIFELINE CURVE

FIGURE 33 ASIA-PACIFIC ANTHRAX TREATMENT MARKET: SNAPSHOT (2021)

FIGURE 34 ASIA-PACIFIC ANTHRAX TREATMENT MARKET: BY COUNTRY (2021)

FIGURE 35 ASIA-PACIFIC ANTHRAX TREATMENT MARKET: BY COUNTRY (2022 & 2029)

FIGURE 36 ASIA-PACIFIC ANTHRAX TREATMENT MARKET: BY COUNTRY (2021 & 2029)

FIGURE 37 ASIA-PACIFIC ANTHRAX TREATMENT MARKET: BY TYPE (2022-2029)

FIGURE 38 ASIA PACIFIC ANTHRAX TREATMENT MARKET: COMPANY SHARE 2021(%)

詳細情報を見る Right Arrow

調査方法

データ収集と基準年分析は、大規模なサンプル サイズのデータ​​収集モジュールを使用して行われます。この段階では、さまざまなソースと戦略を通じて市場情報または関連データを取得します。過去に取得したすべてのデータを事前に調査および計画することも含まれます。また、さまざまな情報ソース間で見られる情報の不一致の調査も含まれます。市場データは、市場統計モデルと一貫性モデルを使用して分析および推定されます。また、市場シェア分析と主要トレンド分析は、市場レポートの主要な成功要因です。詳細については、アナリストへの電話をリクエストするか、お問い合わせをドロップダウンしてください。

DBMR 調査チームが使用する主要な調査方法は、データ マイニング、データ変数が市場に与える影響の分析、および一次 (業界の専門家) 検証を含むデータ三角測量です。データ モデルには、ベンダー ポジショニング グリッド、市場タイムライン分析、市場概要とガイド、企業ポジショニング グリッド、特許分析、価格分析、企業市場シェア分析、測定基準、グローバルと地域、ベンダー シェア分析が含まれます。調査方法について詳しくは、お問い合わせフォームから当社の業界専門家にご相談ください。

カスタマイズ可能

Data Bridge Market Research は、高度な形成的調査のリーダーです。当社は、既存および新規のお客様に、お客様の目標に合致し、それに適したデータと分析を提供することに誇りを持っています。レポートは、対象ブランドの価格動向分析、追加国の市場理解 (国のリストをお問い合わせください)、臨床試験結果データ、文献レビュー、リファービッシュ市場および製品ベース分析を含めるようにカスタマイズできます。対象競合他社の市場分析は、技術ベースの分析から市場ポートフォリオ戦略まで分析できます。必要な競合他社のデータを、必要な形式とデータ スタイルでいくつでも追加できます。当社のアナリスト チームは、粗い生の Excel ファイル ピボット テーブル (ファクト ブック) でデータを提供したり、レポートで利用可能なデータ セットからプレゼンテーションを作成するお手伝いをしたりすることもできます。